Tekmira Delays Start of Cancer Drug Trial, Sees Expanded Roche Partnership in '09 | GenomeWeb

Tekmira Pharmaceuticals this week announced that it has pushed back the expected start date for a phase I study of its siRNA-based cancer therapy PLK1 SNALP to some time in 2010 as it works to incorporate improvements in its drug-delivery technology into the program.

Meanwhile, the company continues to find success on the partnering front, announcing today that Bristol-Myers Squibb has exercised an option to extend its research collaboration with Tekmira through 2009.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.